1.Pre -vs. Post-Anterior Clinoidectomy Measurements of the Optic Nerve, Internal Carotid Artery, and Optico-Carotid Triangle: A Cadaveric Morphometric Study.
Yong Soon HWANG ; Sang Keun PARK ; Hyung Shik SHIN ; Sang Jin KIM ; Joung H LEE ; James EVANS
Journal of Korean Neurosurgical Society 1999;28(8):1082-1088
Anterior clinoid process is a small bony structure but it is very important regarding its location and relationships with neighboring neurovascular, dural, and bony structures. Removal of this process has been used in various modification of standard pterional approach. The authors have speculated how much expansion of operative window could be obtained with anterior clinoidectomy, so we measured the lengths of optic nerve, internal carotid artery, and the length and width of optico-carotid triangle(OCT) before and after extradural anterior clinoidectomy 17 times in 10 cadaveric heads. This procedure provided about two fold increase in the length of optic nerve and OCT, and over three fold expansion in the width of OCT. The results indicate that the addition of this relatively simple and easy procedure to standard approach makes the operative field more comfortable and safe than expected. We believe this procedure can be used routinely with or without combination of wide skull base exposure in cases of such lesions as belows: 1) lesions causing optic nerve or chiasmatic compression, 2) lesions encircling/covering the optic nerve and internal carotid artery, 3) lesions arising from or extending into the optic canal, orbital apex, and paraclinoid region, 4) suprasellar/parasellar lesions with limited operative windows(e.g. prefixed chiasm, infra-optic or subchiasmatic locations or adherence).
Cadaver*
;
Carotid Artery, Internal*
;
Head
;
Optic Nerve*
;
Orbit
;
Skull Base
2.Evaluation of Non-Watertight Dural Reconstruction with Collagen Matrix Onlay Graft in Posterior Fossa Surgery.
Varun R KSHETTRY ; Bjorn LOBO ; Joshua LIM ; Burak SADE ; Soichi OYA ; Joung H LEE
Journal of Korean Neurosurgical Society 2016;59(1):52-57
OBJECTIVE: Many surgeons advocate for watertight dural reconstruction after posterior fossa surgery given the significant risk of cerebrospinal fluid (CSF) leak. Little evidence exists for posterior fossa dural reconstruction utilizing monolayer collagen matrix onlay graft in a non-watertight fashion. Our objective was to report the results of using collagen matrix in a non-watertight fashion for posterior fossa dural reconstruction. METHODS: We conducted a retrospective review of operations performed by the senior author from 2004-2011 identified collagen matrix (DuraGen) use in 84 posterior fossa operations. Wound complications such as CSF leak, infection, pseudomeningocele, and aseptic meningitis were noted. Fisher's exact test was performed to assess risk factor association with specific complications. RESULTS: Incisional CSF leak rate was 8.3% and non-incisional CSF leak rate was 3.6%. Incidence of aseptic meningitis was 7.1% and all cases resolved with steroids alone. Incidence of palpable and symptomatic pseudomeningocele in follow-up was 10.7% and 3.6% respectively. Postoperative infection rate was 4.8%. Previous surgery was associated with pseudomeningocele development (p<0.05). CONCLUSION: When primary dural closure after posterior fossa surgery is undesirable or not feasible, non-watertight dural reconstruction with collagen matrix resulted in incisional CSF leak in 8.3%. Incidence of pseudomeningocele, aseptic meningitis, and wound infection were within acceptable range. Data from this study may be used to compare alternative methods of dural reconstruction in posterior fossa surgery.
Cerebrospinal Fluid
;
Collagen*
;
Follow-Up Studies
;
Incidence
;
Inlays*
;
Meningitis, Aseptic
;
Retrospective Studies
;
Risk Factors
;
Steroids
;
Transplants*
;
Wound Infection
;
Wounds and Injuries
3.Clinical differential diagnosis of usual interstitial pneumonia from nonspecific interstitial pneumonia.
Chang Hyeok AN ; Young Min KOH ; Man Pyo CHUNG ; Gee Young SUH ; Soo Jung KANG ; Kyeong Woo KANG ; Jong Woon AHN ; Si Young LIM ; Ho Joong KIM ; Joung Ho HAN ; Kyung Soo LEE ; O Jung KWON ; Chong H RHEE
Tuberculosis and Respiratory Diseases 2000;48(6):932-943
BACKGROUND: Nonspecific interstitial pneumonitis (NSIP) is most likely to be confused with usual interstitial pneumonitis (UIP). Unlike patients with UIP, the majority of patients with NSIP have a good prognosis, with most patients improving after treatment with corticosteroids. Therefore it is clinically important to differentiate NSIP from UIP. UP to now, the only means of differentiating these two diseases was by means of surgical lung biopsy. American Thoracic Society (ATS) proposed a clinical diagnostic criterial for UIP to provide assistance to clinicians in its diagnosis without surgical lung biopsy. This study is aimed to investigate whether there were clinical and radiological differences between NSIP and UIP, and the usefulness of ATS clinical diagnostic criteria for UIP in Korea. METHODS: we studied 60 patients with UIP and NSIP confirmed by surgical lung biopsy. Clinical manifestations, pulmonary function test, arterial blood gas analysis, bronchoalveolar lavage (BAL), and high resolution computed tomography (HRCT) were evaluated and analyzed by Chi-square test or t-test. The clinical criteria for UIP proposed by ATS were applied to all patients with idiopathic interstitial pneumonia. RESULTS: Forty-two patients with UIP and 18 with NSIP were pathologically identified. Among the 18 patients with NSIP (M : F = 1 : 17), the mean age was 55.2± 8.4 (44~73)yr. Among the 42 patients with UIP (M : F = 33 : 9), the mean age was 59.5±7.1 (45~74) yr (p=0.0460. Fever was more frequent in NSIP (39%) (p=0.034), but clubbing was frequently observed in UIP (33%) (p=0.023). BAL lymphocytosis was more frequent (23%) (p=0.0001) and CD4/CD8 ratio was lower in NSIP (p=0.045). On HRCT, UIP frequently showed honeycomb appearance (36 of 42 patients) through not in NSIP (p=0.0001). Six of 42 UIP patients (14.3%) met the ATS clinical criteria for IPF, and 3 of 16 NSIP patients (18.8%) met the diagnostic criteria. CONCLUSION: Being a relatively young female and having short duration of illness, fever, BAL lymphocytosis, low CD4/CD8 ratio with the absence of clubbing and honeycomb appearance in HRCT increase the likelihood of the illness being NSIP. The usefulness of ATS clinical diagnostic criteria for UIP may be low in Korea.
Adrenal Cortex Hormones
;
Biopsy
;
Blood Gas Analysis
;
Bronchoalveolar Lavage
;
Diagnosis
;
Diagnosis, Differential*
;
Female
;
Fever
;
Humans
;
Idiopathic Interstitial Pneumonias
;
Idiopathic Pulmonary Fibrosis*
;
Korea
;
Lung
;
Lung Diseases, Interstitial*
;
Lymphocytosis
;
Prognosis
;
Pulmonary Fibrosis
;
Respiratory Function Tests
4.Two Cases of Fibrosing Mediastinitis Caused by Tuberculosis.
Ki Hyun KIM ; Ho Cheol KIM ; Man Pyo CHUNG ; Ho Joong KIM ; Kyung Soo LEE ; Joung Ho KIM ; O Jung KWON ; Chong H RHEE ; Yong Chol HAN
Tuberculosis and Respiratory Diseases 1997;44(5):1146-1157
Fibrosing mediastinitis is a rare disease which is characterized by excessive fibrosis of mediastinum and symptoms caused by compression and obstruction of mediastinal structures. Afthough the pathogenesis of this disease is unknown, granulomatous infection is cinsidered to be the most common cause of this disease. Histoplasmosis is the most common etiology, especially in the endemic areas in United States. Tuberculosis is another etiology of fibrosing mediastinitis. We experienced two cases of fibrosing mediastinitis associated with tuberculous infection.
Fibrosis
;
Histoplasmosis
;
Mediastinitis*
;
Mediastinum
;
Rare Diseases
;
Tuberculosis*
;
United States
5.Clinical Features and Treatment Response in 18 Cases with Idiopathic Nonspecific Interstitial Pneumonia.
Eun Hae KANG ; Man Pyo CHUNG ; Soo Jung KANG ; Chang Hyeok AN ; Jong Woon AHN ; Joung Ho HAN ; Kyung Soo LEE ; Si Young LIM ; Gee Yiung SUH ; Ho Joong KIM ; O Jung KWON ; Chong H RHEE
Tuberculosis and Respiratory Diseases 2000;48(4):530-542
BACKGROUND: Nonspecific interstitial pneumonia (NSIP) has been reported recently to show much better response to medical treatment and better prognosis compared with idiopathic UIP. However, clinical characteristics of idiopathic NSIP discriminating from UIP have not been defined clearly. METHOD: Among 120 patients with biopsy-proven diffuse interstitial lung diseases between July 1996 and March 2000 at Samsung Medical Center, 18 patients with idiopathic NSIP were included in this study. Retrospective chart review and radiographic analysis were performed. RESULTS: 1) At diagnosis, 17 patients were female and average age was 55.2 +/-8.4 years (44~73 years). The average duration from development of respiratory symptom to surgical lung biopsy was 9.9+/-17.1 months. Increase in bronchoalveolar lavage fluid lymphocytes (23.0 +/-13.1%) was noted. On HRCT, ground glass and irregular linear opacity were seen but honeycombing was absent in all patients. 2) Corticosteroids were initially given to 13 patients of whom medication was stopped in 3 patients due to severe side effects. Further medical therapy was impossible in 1 patient who experienced streroid-induced psychosis. Herpes zoster (n=3), tuberculosis (n=1), avascu lar necrosis of hip (n=1), cataract (n=2) and diabetes mellitus (n=1) developed during prolonged corticosteroid administration. Of 7 patients receiving oral cyclophosphamide therapy, hemorrhagic cystitis hindered one patient from continuous medication. 3) After medical treatment, 14 of 17 patients improved and 3 patients remained stable (mean w-up ; 24.1+/-11.2 months). FVC increased by 20.2 +/-11.2% of predicted value and the extent of ground glass opacity on HRCT decreased significantly (15.7+/-14.7%). 4) Of 14 patients who had stopped medication, 5 showed recurrence of NSIP and 2 aggravated during steroid tapering. All patients with recurrence showed deterioration within one year after completion of initial treatment. CONCLUSION: Since idiopathic NSIP has unique clinical profiles and shows a good prognosis, differential diagnosis from UIP and aggressive medical treatment are needed.
Adrenal Cortex Hormones
;
Biopsy
;
Bronchoalveolar Lavage Fluid
;
Cataract
;
Cyclophosphamide
;
Cystitis
;
Diabetes Mellitus
;
Diagnosis
;
Diagnosis, Differential
;
Female
;
Glass
;
Herpes Zoster
;
Hip
;
Humans
;
Idiopathic Pulmonary Fibrosis
;
Lung
;
Lung Diseases, Interstitial*
;
Lymphocytes
;
Necrosis
;
Prognosis
;
Psychotic Disorders
;
Recurrence
;
Retrospective Studies
;
Tuberculosis
6.A Case of Diffuse Alveolar Damage Induced by Cyclophosphamide.
Sang Su BAE ; Mun Hee BAE ; Hyung Suk PARK ; Jeong Woong PARK ; Gee Young SUH ; Man Pyo CHUNG ; Joung Ho HAN ; O Jung KWON ; Kyung Soo LEE ; Chong H RHEE
Tuberculosis and Respiratory Diseases 1998;45(2):429-436
Approximately 100 drugs have been reported to affect the lungs adversely. Among these, pulmonary toxicity caused by antieneoplastic agent is being recognized more frequently. Cyclophosphamide is an immunosuppressive alkylating agent used for the treatment of a wide variety of malignant and nonmalignant diseases. The incidence of pulmonary toxicity is probably less than 1 percent The first case was reported in 1967. Since then, more than 20 well-documented cases of pulmonary toxicity associated with cyclophosphamide have been reported in the literature. In Korea, three patients were identified with cyclophosphamide-induced lung disease. The typical features of toxicity include dyspnea, fever, cough, new parenchymal infiltrates, gas exchangs abnormalities on pulmonary function tests, and pleural thickening on chest roentgenogram. The best approach to management is early diagnosis, discontinuation of the offending drug and administration of corticosteroid therapy. Recently, we experienced a case of diffuse alveolar damage induced by cyclophosphamide. The patient presented with early-onset pulmonary toxicity and died of repiratory failure despite early use of corticosteroid.
Cough
;
Cyclophosphamide*
;
Dyspnea
;
Early Diagnosis
;
Fever
;
Humans
;
Incidence
;
Korea
;
Lung
;
Lung Diseases
;
Respiratory Function Tests
;
Thorax
7.Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
Hee Tae YU ; Pil Sung YANG ; Jinseub HWANG ; Soorack RYU ; Eunsun JANG ; Tae Hoon KIM ; Jae Sun UHM ; Jong Youn KIM ; Hui Nam PAK ; Moon Hyoung LEE ; Gregory Y H LIP ; Boyoung JOUNG
Korean Circulation Journal 2020;50(3):267-277
BACKGROUND AND OBJECTIVES:
Nationwide social inequalities of oral anticoagulation (OAC) usage after the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) have not been well identified in patients with atrial fibrillation (AF). This study assessed overall rate and social inequalities of OAC usage after the introduction of NOAC in Korea.
METHODS:
Between January 2002 and December 2016, we identified 888,540 patients with AF in the Korea National Health Insurance system database. The change of OAC rate in different medical systems after the introduction of NOAC were evaluated.
RESULTS:
In all population, overall OAC use increased from 13.2% to 23.4% (p for trend <0.001), and NOAC use increased from 0% to 14.6% (p for trend <0.001). Compared with pre-reimbursement (0.48%), the annual increase of OAC use was significantly higher after partial (1.16%, p<0.001), and full reimbursement of OAC (3.72%, p<0.001). Full reimbursement of NOAC (adjusted odds ratio, 2.10; 95% confidence interval, 2.04–2.15) was independently associated with higher OAC use. However, the difference of overall OAC usage between tertiary referral hospitals and nursing or public health centers increased from 17.9% in 2010 to 36.8% in 2016. Moreover, usage rate of NOAC was significantly different among different medical systems from 37.2% at the tertiary referral hospital and 5.5% at nursing or public health centers.
CONCLUSIONS
Introduction of NOACs in routine practice for stroke prevention in AF was associated with improved rates of overall OAC use. However, significant practice-level variations in OAC and NOAC use remain producing social inequalities of OAC despite full reimbursement.
8.Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
Hee Tae YU ; Pil Sung YANG ; Jinseub HWANG ; Soorack RYU ; Eunsun JANG ; Tae Hoon KIM ; Jae Sun UHM ; Jong Youn KIM ; Hui Nam PAK ; Moon Hyoung LEE ; Gregory Y H LIP ; Boyoung JOUNG
Korean Circulation Journal 2020;50(3):267-277
BACKGROUND AND OBJECTIVES: Nationwide social inequalities of oral anticoagulation (OAC) usage after the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) have not been well identified in patients with atrial fibrillation (AF). This study assessed overall rate and social inequalities of OAC usage after the introduction of NOAC in Korea.METHODS: Between January 2002 and December 2016, we identified 888,540 patients with AF in the Korea National Health Insurance system database. The change of OAC rate in different medical systems after the introduction of NOAC were evaluated.RESULTS: In all population, overall OAC use increased from 13.2% to 23.4% (p for trend <0.001), and NOAC use increased from 0% to 14.6% (p for trend <0.001). Compared with pre-reimbursement (0.48%), the annual increase of OAC use was significantly higher after partial (1.16%, p<0.001), and full reimbursement of OAC (3.72%, p<0.001). Full reimbursement of NOAC (adjusted odds ratio, 2.10; 95% confidence interval, 2.04–2.15) was independently associated with higher OAC use. However, the difference of overall OAC usage between tertiary referral hospitals and nursing or public health centers increased from 17.9% in 2010 to 36.8% in 2016. Moreover, usage rate of NOAC was significantly different among different medical systems from 37.2% at the tertiary referral hospital and 5.5% at nursing or public health centers.CONCLUSIONS: Introduction of NOACs in routine practice for stroke prevention in AF was associated with improved rates of overall OAC use. However, significant practice-level variations in OAC and NOAC use remain producing social inequalities of OAC despite full reimbursement.
Anticoagulants
;
Atrial Fibrillation
;
Humans
;
Insurance
;
Korea
;
National Health Programs
;
Nursing
;
Odds Ratio
;
Public Health
;
Socioeconomic Factors
;
Stroke
;
Tertiary Care Centers
9.Risk for osteoporotic fractures in patients with atrial fibrillation using different oral anticoagulants
Daehoon KIM ; Pil‑Sung YANG ; Jung‑Hoon SUNG ; , Eunsun JANG ; Hee Tae YU ; Tae‑Hoon KIM ; Jae‑Sun UHM ; Jong‑Youn KIM ; Hui‑Nam PAK ; Moon‑Hyoung LEE ; Gregory Y. H. LIP ; Boyoung JOUNG
International Journal of Arrhythmia 2021;22(1):4-
Background:
We aimed to investigate the comparative risk of fracture among patients with atrial fibrillation (AF) treated with warfarin or non-vitamin K antagonist oral anticoagulants (NOACs).
Methods:
Using the Korean National Health Insurance Service database, patients with AF who received a prescrip‑ tion for apixaban, dabigatran, rivaroxaban, or warfarin between 2013 and 2016 were included. Risk of major fractures (osteoporotic hip, vertebral, or pelvic fractures) were compared using inverse probability of treatment weighting.
Results:
There were 70,481 patients identified (41.3% women; mean [SD] age 70.5 [11.3] years); 16,992 apixaban, 22,514 dabigatran, 27,998 rivaroxaban, and 29,390 warfarin users. During a median follow-up of 390 days, 2412 major fractures occurred with weighted incidences per 100 patient-years of 2.56 for apixaban, 2.39 for dabigatran, 2.78 for rivaroxaban, and 3.43 for warfarin. NOAC use was associated with a lower risk for fracture than warfarin use: HR 0.70 (95% confidence interval [CI] 0.57–0.86) for apixaban, HR 0.69 (95% CI 0.60–0.78) for dabigatran, and HR 0.79 (95% CI 0.70–0.90) for rivaroxaban. In head-to-head comparisons between NOACs, there was no significant difference between apixaban and dabigatran. Rivaroxaban was associated with a higher risk for fracture than dabigatran (HR 1.15, 95% CI 1.02–1.31).
Conclusion
In patients with AF, NOAC use may result in a lower risk for osteoporotic fracture compared with warfa‑ rin use. Fracture risk does not seem to be altered by the choice of NOAC type, except for rivaroxaban. These associa‑ tions may help inform benefit–risk assessments when choosing between the different anticoagulant types.
10.Risk for osteoporotic fractures in patients with atrial fibrillation using different oral anticoagulants
Daehoon KIM ; Pil‑Sung YANG ; Jung‑Hoon SUNG ; , Eunsun JANG ; Hee Tae YU ; Tae‑Hoon KIM ; Jae‑Sun UHM ; Jong‑Youn KIM ; Hui‑Nam PAK ; Moon‑Hyoung LEE ; Gregory Y. H. LIP ; Boyoung JOUNG
International Journal of Arrhythmia 2021;22(1):4-
Background:
We aimed to investigate the comparative risk of fracture among patients with atrial fibrillation (AF) treated with warfarin or non-vitamin K antagonist oral anticoagulants (NOACs).
Methods:
Using the Korean National Health Insurance Service database, patients with AF who received a prescrip‑ tion for apixaban, dabigatran, rivaroxaban, or warfarin between 2013 and 2016 were included. Risk of major fractures (osteoporotic hip, vertebral, or pelvic fractures) were compared using inverse probability of treatment weighting.
Results:
There were 70,481 patients identified (41.3% women; mean [SD] age 70.5 [11.3] years); 16,992 apixaban, 22,514 dabigatran, 27,998 rivaroxaban, and 29,390 warfarin users. During a median follow-up of 390 days, 2412 major fractures occurred with weighted incidences per 100 patient-years of 2.56 for apixaban, 2.39 for dabigatran, 2.78 for rivaroxaban, and 3.43 for warfarin. NOAC use was associated with a lower risk for fracture than warfarin use: HR 0.70 (95% confidence interval [CI] 0.57–0.86) for apixaban, HR 0.69 (95% CI 0.60–0.78) for dabigatran, and HR 0.79 (95% CI 0.70–0.90) for rivaroxaban. In head-to-head comparisons between NOACs, there was no significant difference between apixaban and dabigatran. Rivaroxaban was associated with a higher risk for fracture than dabigatran (HR 1.15, 95% CI 1.02–1.31).
Conclusion
In patients with AF, NOAC use may result in a lower risk for osteoporotic fracture compared with warfa‑ rin use. Fracture risk does not seem to be altered by the choice of NOAC type, except for rivaroxaban. These associa‑ tions may help inform benefit–risk assessments when choosing between the different anticoagulant types.